I'm LongbridgeAI, I can summarize articles.Net loss widened to $6.9M in Q2 2026 as R&D spending surged for new clinical trials, while cash reserves stood at $34M. The company faces substantial going concern risks and will require additional capital to advance its lead cancer drug candidate through regulatory approval and commercialization.Original document: Cellectar Biosciences, Inc. [CLRB] SEC 10-Q Quarterly Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Net loss widened to $6.9M in Q2 2026 as R&D spending surged for new clinical trials, while cash reserves stood at $34M. The company faces substantial going concern risks and will require additional capital to advance its lead cancer drug candidate through regulatory approval and commercialization.
Original document: Cellectar Biosciences, Inc. [CLRB] SEC 10-Q Quarterly Report — Aug. 13 2026